DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAlnylam Pharmaceuticals

About this trial

The purpose of this study is to:

* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Eligibility criteria

Qualifiers

Has a diagnosis of ATTR-CM

Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Disqualifiers

Is enrolled in an interventional clinical trial

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

2,000 Participants
are grouped into 1 trial group

Locations

4
Clinical Trial Site34102, NaplesFlorida, United States
Clinical Trial Site02215, BostonMassachusetts, United States
Clinical Trial Site08901, New BrunswickNew Jersey, United States
Clinical Trial Site38120, MemphisTennessee, United States

Sponsors and collaborators

Alnylam Pharmaceuticals

Lead sponsor